June 20, 2018
Novo Nordisk shows oral semaglutide more effective in lowering glucose and body weight than Victoza
Novo Nordisk on Wednesday said that it has completed headline results of the phase 3a trials PIONEER 4 comparing oral…
Pharmaceuticals, Biotechnology and Life Sciences
Novo Nordisk on Wednesday said that it has completed headline results of the phase 3a trials PIONEER 4 comparing oral…
The U.S. Food and Drug Administration (FDA) has approved a new indication for Novo Nordisk’s Victoza (liraglutide) to reduce the risk of major adverse cardiovascular (CV) events in adults with type 2 diabetes and established CV disease.